Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis

Annals of Surgery

Volumn 226, Issue 1, 1997, Pages 77-84

  Slotman, Gus J ^a   Quinn, James V ^a   Wry, Philip C ^a   Brathwaite, Collin E M ^a   Friedman, Bruce M ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYTOKINE; ICOSANOID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; PLACEBO; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITALIZATION; HUMAN; ICOSANOID METABOLISM; IMMUNE RESPONSE; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

CYTOKINES; DOUBLE-BLIND METHOD; EICOSANOIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0030828672     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199707000-00011     Document Type: Article

References (27)

1. Bone RC, Fisher CJ, Clemmer TP, et al. The sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17:389-393.
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655.
3. Ohlsson K, Bjork P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-552.
4. Fisher CJ, Dhainaut JFA, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271:1836-1843.
5. Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-l receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22:12.
6. Dinarello CA, Okusawa S, Gelfand JA, Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclo-oxygenase inhibition. Mol Cell Mech Sep Shock 1989; 243-263.
7. Mugridge KG, Donati D, Silvestri S, Parente L. Arachidonic acid lipoxygenation may be involved in interleukin-l induction of prostaglandin biosynthesis. J Pharmacol Exp Ther 1989; 250:714-720.
8. Calandra T, Glauser MP. Cytokines and septic shock. Diagn Microbiol Infect Dis 1990; 13:377-381.
9. Slotman GJ, Friedman B, Brathwaite C, et al. Interleukin-1 mediates increased plasma levels of eicosanoids and cytokines in patients with sepsis syndrome. Shock 1995; 4:318-323.
10. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill; 1956.
11. Dinarello CA. Interleukin-1 and the effects of cyclo-oxygenase inhibitors on its biological activities. Bull N Y Acad Med 1989; 65:80-92.
12. Endres S, Cannon JG, Ghorbani R, et al. In vitro production of IL1β, IL1α, TNF and IL2 in healthy subjects: distribution. effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 1989; 19:2327-2333.
13. Spinas GA, Bloesch D, Keller U, et al. Pretreatment with Ibuprofen augments circulating tumor necrosis factor-α, interleukin-6, and elastase during acute endotoxemia. J Infect Dis 1991; 163:89-95.
14. Bull HA, Dowd PM. Interleukin-1 potentiates histamine-induced release of prostacyclin from human endothelial cells. Br J Pharmacol 1990; 101:703-709.
15. Maier JAM, Hing T, Macing T. Cyclooxygenase is an immediate early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 1990; 265:10805-10808.
16. Navarra P, Tsagarakis S, Faria M, et al. Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology 1990; 128:37-44.
17. Breviario F, Proserpio P, Bertocchi F, et al. Interleukin-1 stimulates prostacyclin production by cultured human endothelial cells by increasing arachidonic acid mobilization and conversion. Arteriosclerosis 1990; 10:129-134.
18. Santos M, Woolley D, Quinn J, Slotman GJ. Interleukin-l (IL-1) mediates hemodynamic dysfunction and eicosanoid release during graded bacteremia. Crit Care Med 1995; 23:A285.
19. Woodward DP, Weichman BM, Gill CA, Wasserman MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983; 25:131-142.
20. Scheffer J, Konig W, Hacker J, Goebel W. Bacterial adherence and hemolysin production from Escherichia coli induces histamine and leukotriene release from various cells. Infect Immun 1985; 50:271-278.
21. 4 induces lung generation of tumor necrosis factor-α that in turn mediates neutrophil diapedesis. Surgery 1993; 113:297-303.
22. Knöller J, Brom J, Schönfeld, König W. Influence of ciprofloxacin on leukotriene generation from various cells in vitro. J Antimicrob Chemother 1989; 25:605-612.
23. Bailly S, Mahe Y, Ferrua B, et al. Quinolone-induced differential modification of IL-1α and IL-1β production by LPS-stimulated human monocytes. Cell Immunol 1990; 128:277-288.
24. Fischer E, Marano MA, Van See KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-1557.
25. Schirmer WJ, Schirmer JM, Fry DE. Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia. Arch Surg 1989; 124:445-448.
26. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474.
27. Waage A, Espevik T. Interleukin-1 potentiates the lethal effect of tumor necrosis factor a/cachectin in mice. J Exp Med 1988; 167:1987-1992.